Moonlight Therapeutics $3M CRO Battle Card

🚀 Battle Card: Moonlight Therapeutics

• Samir Patel, CEO 📧 samir.patel@moonlighttx.com

• FDA cleared the IND for MOON101 and secured new DHA & NIAID funding → Source Another potent Moonlight Therapeutics sales trigger for CRO adoption.

• Regulatory complexity of initiating first-in-human peanut allergy trials

• Funding gaps to expand pipeline beyond MOON101

• Primary: IND & clinical trial management (CRO services) → accelerate SURVEYOR trial launch

• Expansion: Grant writing & regulatory consulting → unlock DHA & NIAID cooperative funding

• HQ: Atlanta, GA

• Employees: ≈ 30

• Rev: ≈ $1 M

• Website: moonlighttx.com

🤼 Competitive Intel

• Parexel — CRO / Clinical Trial Ops
• Unique edge: Deep IND and early-phase expertise
• Evaluated by CEO & Head of Clinical

• ICON — CRO / Global Trials
• Unique edge: Scaled patient recruitment networks
• Evaluated by VP Operations for enrollment speed

• Medpace — CRO / End-to-End Solutions
• Unique edge: Integrated lab and central monitoring
• Evaluated by Head of Clinical & Finance

• Covance (Labcorp) — Lab Services / Preclinical
• Unique edge: Broad assay and bioanalytical capabilities
• Evaluated by R&D and QA leads

• Charles River Labs — Preclinical / Toxicology
• Unique edge: In-house allergen immunology models
• Evaluated by Head of R&D for platform validation

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑<your company>❑
OFFER_BRIEF   = ❑Integrated IND & clinical trial management❑
PROOF_METRIC  = ❑Reduced trial launch time by 30%❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑friendly❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Samir
COMPANY     = Moonlight Therapeutics
DEPT        = Clinical Development
SIZE        = ≈ 30
BOTTLENECK  = Regulatory complexity of initiating first-in-human peanut allergy trials
EVENT       = $3M funding
DETAIL      = FDA cleared the IND for MOON101
PAIN        = Regulatory complexity of initiating first-in-human peanut allergy trials
SRC         = https://vcnewsdaily.com/moonlight-therapeutics/venture-capital-funding/nzznysngtn
SIM_CO      = ≈ TBD
WIN_METRIC  = ≈ TBD
NEXT_SIZE   = ≈ 50
EMP_EST     = ≈ 30
REV_EST     = ≈ $1M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: ≈ 30-person Clinical Development

Samir—noticed your Clinical Development team is ≈ 30.

That’s when Regulatory complexity of initiating first-in-human peanut allergy trials slows growth.

We helped ≈ TBD fix this with Integrated IND & clinical trial management.

Result: ≈ TBD.  
Quick call?

PS—next bottleneck hits ≈ 50.

DM ≤45 words, TONE:
Saw your post about FDA cleared the IND for MOON101 — Regulatory complexity of initiating first-in-human peanut allergy trials.  
Integrated IND & clinical trial management. Reduced trial launch time by 30%.  
Quick chat?